GSK’s Horlicks Review Plan - Some Early Expectations In India
Executive Summary
A potential sale of Horlicks could impact market dynamics significantly in India where the popular malt beverage holds a dominant position but has seen competition build up. GlaxoSmithKline, though, has underscored that the review plan had nothing to do with the product’s "critical mass".
You may also be interested in...
GSK Invests In OTC Production, Prepares To Divest Horlicks Nutritional Business
Latest consumer health investment was $36m upgrade to a Canadian facility, which by mid-2019 will begin making Voltaren OTC topical gel products. GSK's next move in consumer health divestment is its pending sale of its Horlicks business.
GSK Invests In OTC Production, Prepares To Divest Horlicks Nutritional Business
Latest consumer health investment was $36m upgrade to a Canadian facility, which by mid-2019 will begin making Voltaren OTC topical gel products. GSK's next move in consumer health divestment is its pending sale of its Horlicks business.
GSK Divesting Horlicks Nutritional Business, Investing In OTC Production
Latest consumer health investment was $36m upgrade to a Canadian facility, which by mid-2019 will begin making Voltaren OTC topical gel products. GSK's next move in consumer health divestment is its pending sale of its Horlicks business.